CN105213336B - 一种丙谷胺药物组合物 - Google Patents
一种丙谷胺药物组合物 Download PDFInfo
- Publication number
- CN105213336B CN105213336B CN201510660128.5A CN201510660128A CN105213336B CN 105213336 B CN105213336 B CN 105213336B CN 201510660128 A CN201510660128 A CN 201510660128A CN 105213336 B CN105213336 B CN 105213336B
- Authority
- CN
- China
- Prior art keywords
- proglumide
- pharmaceutical composition
- parts
- monohydrogen phosphate
- calcium monohydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 title claims abstract description 47
- 229960003857 proglumide Drugs 0.000 title claims abstract description 47
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims abstract description 16
- 235000019700 dicalcium phosphate Nutrition 0.000 claims abstract description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 6
- 239000000853 adhesive Substances 0.000 claims abstract 2
- 230000001070 adhesive effect Effects 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 7
- 206010013786 Dry skin Diseases 0.000 claims description 5
- 239000011122 softwood Substances 0.000 claims description 3
- 235000020985 whole grains Nutrition 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 2
- 239000012670 alkaline solution Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 210000000232 gallbladder Anatomy 0.000 description 4
- 102100021022 Gastrin Human genes 0.000 description 3
- 108010052343 Gastrins Proteins 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 230000027119 gastric acid secretion Effects 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 208000011906 peptic ulcer disease Diseases 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000004575 stone Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 description 2
- 102000052874 Gastrin receptors Human genes 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- WSGYTJNNHPZFKR-UHFFFAOYSA-N 3-hydroxypropanenitrile Chemical compound OCCC#N WSGYTJNNHPZFKR-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- BPYKTIZUTYGOLE-UHFFFAOYSA-N billirubin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(C=C3C(=C(C=C)C(=O)N3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510660128.5A CN105213336B (zh) | 2015-10-14 | 2015-10-14 | 一种丙谷胺药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510660128.5A CN105213336B (zh) | 2015-10-14 | 2015-10-14 | 一种丙谷胺药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105213336A CN105213336A (zh) | 2016-01-06 |
CN105213336B true CN105213336B (zh) | 2019-01-22 |
Family
ID=54982858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510660128.5A Active CN105213336B (zh) | 2015-10-14 | 2015-10-14 | 一种丙谷胺药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105213336B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4576951A (en) * | 1983-12-12 | 1986-03-18 | Rotta Research Laboratorium S.P.A. | Proglumide, pharmaceutical preparations and compositions including it for use in human pain relief |
CN102138913A (zh) * | 2011-03-24 | 2011-08-03 | 江苏苏南药业实业有限公司 | 一种盐酸雷尼替丁胶囊及其生产方法 |
-
2015
- 2015-10-14 CN CN201510660128.5A patent/CN105213336B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4576951A (en) * | 1983-12-12 | 1986-03-18 | Rotta Research Laboratorium S.P.A. | Proglumide, pharmaceutical preparations and compositions including it for use in human pain relief |
CN102138913A (zh) * | 2011-03-24 | 2011-08-03 | 江苏苏南药业实业有限公司 | 一种盐酸雷尼替丁胶囊及其生产方法 |
Non-Patent Citations (1)
Title |
---|
丙谷胺片试制;范文元等;《医药工业》;19830131(第01期);第35-36页,第35页试验号III及左栏第1段 |
Also Published As
Publication number | Publication date |
---|---|
CN105213336A (zh) | 2016-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102861106A (zh) | 一种复方氨酚烷胺微丸的制备方法 | |
CN101273973B (zh) | 一种含有枸橼酸莫沙必利的分散片 | |
CN104800175A (zh) | 吉非替尼片的制备方法 | |
CN101695480A (zh) | 盐酸奥洛他定分散片及其制备方法和质量控制方法 | |
CN102276516B (zh) | 一种苯磺酸左旋氨氯地平晶体、其制备方法及含有该晶体的药物组合物 | |
CN105412026A (zh) | 盐酸阿考替胺片及其制备方法 | |
CN105213336B (zh) | 一种丙谷胺药物组合物 | |
CN101361869B (zh) | 哮喘宁片的质量控制方法 | |
CN102697743B (zh) | 苯磺酸左旋氨氯地平片及其制剂工艺 | |
CN105395506B (zh) | 一种盐酸可乐定缓释片 | |
CN103191065A (zh) | 塞来昔布新剂型及其制备方法 | |
CN104523651B (zh) | 一种伏格列波糖胶囊及其制备方法 | |
CN101690752A (zh) | 一种药物组合物的质量控制方法 | |
CN106053663A (zh) | 一种肠溶缓释片剂的释放度测定方法 | |
CN106018618A (zh) | 草酸艾司西酞普兰片剂组合物和质控方法 | |
CN106265557A (zh) | 含有替格瑞洛的药物组合物 | |
CN109953966A (zh) | 一种含有瑞博西尼的药物组合物及其制备方法 | |
CN105640919B (zh) | 尼麦角林胶囊及其制备方法 | |
CN105764509B (zh) | 达比加群酯或其盐的投药制剂及其制备方法 | |
CN104138365B (zh) | 一种替米沙坦胶囊剂及其制备方法 | |
CN104840460A (zh) | 一种含有缬沙坦和氨氯地平的药物组合物 | |
CN103193700B (zh) | 一种苯磺酸左旋氨氯地平晶体及含有该晶体的药物组合物 | |
CN105596341B (zh) | 一种琥珀酸曲格列汀固体制剂及制备方法 | |
CN104644558A (zh) | 一种西尼地平的固体分散体及其制备方法 | |
CN103385863A (zh) | 一种薁磺酸钠缓释制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Proglumide pharmaceutical composition Effective date of registration: 20210730 Granted publication date: 20190122 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021430000029 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211014 Granted publication date: 20190122 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021430000029 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
CP02 | Change in the address of a patent holder |
Address after: No.8 Kangpu Avenue, high tech Industrial Park, Hanshou County, Changde City, Hunan Province, 415900 Patentee after: KAMP PHARMACEUTICALS Co.,Ltd. Address before: 12 / F, building B, Lugu information port, 658 Lugu Avenue, high tech Zone, Changsha City, Hunan Province, 410205 Patentee before: KAMP PHARMACEUTICALS Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Proglumide pharmaceutical composition Effective date of registration: 20211028 Granted publication date: 20190122 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021980011259 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |